Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results (Pituitary, (2021), 10.1007/s11102-021-01163-2)

Artak Labadzhyan*, L. B. Nachtigall, M. Fleseriu, M. B. Gordon, M. Molitch, L. Kennedy, S. L. Samson, Y. Greenman, N. Biermasz, M. Bolanowski, A. Haviv, W. Ludlam, G. Patou, C. J. Strasburger

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

The article ‘Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results’, written by Artak Labadzhyan, L B Nachtigall, M Fleseriu, M B Gordon, M Molitch, L Kennedy, S L Samson, Y Greenman, N Biermasz, M Bolanowski, A Haviv, W Ludlam, G Patou and C J Strasburger was originally published electronically on the publisher’s internet portal on 25 June 2021 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 15 July 2021 to

Original languageEnglish (US)
JournalPituitary
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results (Pituitary, (2021), 10.1007/s11102-021-01163-2)'. Together they form a unique fingerprint.

Cite this